The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis by Arrieta, Oscar et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Cancer
Open Access Research article
The progressive elevation of alpha fetoprotein for the diagnosis of 
hepatocellular carcinoma in patients with liver cirrhosis
Oscar Arrieta*1,3, Bernardo Cacho†2, Daniela Morales-Espinosa†1, 
Ana Ruelas-Villavicencio2, Diana Flores-Estrada1 and Norma Hernández-
Pedro1
Address: 1Department of Medical Oncology, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico, 2Department of Internal Medicine, 
Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán" (INCMNSZ), Mexico City, Mexico and 3Universidad Nacional Autónoma 
de México (UNAM), Mexico City, Mexico
Email: Oscar Arrieta* - ogar@servidor.unam.mx; Bernardo Cacho - bernardocacho@doctor.com; Daniela Morales-
Espinosa - danamores@yahoo.com; Ana Ruelas-Villavicencio - lemlogar@hotmail.com; Diana Flores-Estrada - dfe15@yahoo.com.mx; 
Norma Hernández-Pedro - noryhp@hotmail.com
* Corresponding author    †Equal contributors
Abstract
Background: Hepatocellular carcinoma is the most common cause of primary liver neoplasms and
is one of the main causes of death in patients with liver cirrhosis. High Alpha fetoprotein serum
levels have been found in 60–70% of patients with Hepatocellular carcinoma; nevertheless, there
are other causes that increase this protein. Alpha fetoprotein levels ≥200 and 400 ng/mL in patients
with an identifiable liver mass by imaging techniques are diagnostic of hepatocellular carcinoma with
high specificity.
Methods: We analysed the sensitivity and specificity of the progressive increase of the levels of
alpha fetoprotein for the detection of hepatocellular carcinoma in patients with liver cirrhosis.
Seventy-four patients with cirrhosis without hepatocellular carcinoma and 193 with hepatic lesions
diagnosed by biopsy and shown by image scans were included. Sensitivity and specificity of
transversal determination of alpha fetoprotein ≥ 200 and 400 ng/mL and monthly progressive
elevation of alpha fetoprotein were analysed. Areas under the ROC curves were compared.
Positive and negative predictive values adjusted to a 5 and 10% prevalence were calculated.
Results: For an elevation of alpha fetoprotein ≥ 200 and 400 ng/mL the specificity is of 100% in
both cases, with a sensitivity of 36.3 and 20.2%, respectively. For an alpha fetoprotein elevation rate
≥7 ng/mL/month, sensitivity was of 71.4% and specificity of 100%. The area under the ROC curve
of the progressive elevation was significantly greater than that of the transversal determination of
alpha fetoprotein. The positive and negative predictive values modified to a 10% prevalence are of:
98.8% and 96.92%, respectively; while for a prevalence of 5% they were of 97.4% and 98.52%,
respectively.
Conclusion: The progressive elevation of alpha fetoprotein ≥7 ng/mL/month in patients with liver
cirrhosis is useful for the diagnosis of hepatocellular carcinoma in patients that do not reach αFP
levels ≥200 ng/mL. Prospective studies are required to confirm this observation.
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Background
Hepatocellular carcinoma (HCC) is the most common
cause of primary liver neoplasms and the fourth most fre-
quent type of cancer worldwide with an increasing inci-
dence, causing one million deaths per year[1]. Nowadays,
therapeutic options are still not efficient, reaching a global
survival rate of 3–10% at 5 years after diagnosis. The
major risk factors associated to the development of HCC
are infection with hepatitis B virus (HBV), hepatitis C
virus (HCV) and cirrhosis of any cause[2]. HCC is one of
the main causes of death in patients with Liver Cirrhosis
(LC)[3]. The annual risk to develop HCC in patients with
LC is 5% (1–7%), with a published prevalence between
7.4 and 23% found in necropsies of this group of patients.
Cirrhosis is present in 80–90% of patients with this type
of cancer [3].
Alpha-fetoprotein (αFP) is a protein of fetal component
produced during the embryonic period by the visceral
endoderm of the gestational sac and, later on, by the liver.
Its re-expression in patients with HCC has been described
for over 40 years. Some studies have demonstrated that
the presence of elevated levels of αFP in patients with LC
is a risk factor for the development of HCC [4-6], thus sug-
gesting that increased αFP-production in patients with LC
might reflect, largely and abnormal or altered liver cell
regeneration. High αFP serum levels have been found in
60–70% of patients with HCC; nevertheless, there are
other causes of increased levels, such as cirrhosis, lung
cancer, biliary cancer, gastric cancer, pancreatic cancer, ter-
atocarcinoma of the testis, spherocytosis and tyrosine-
mia[7]. Alpha fetoprotein levels <20 ng/mL are
considered normal; with this value as the upper level, this
diagnostic test has a sensitivity of 41–65%[4,8,9] to diag-
nose HCC, but a low specificity. The αFP levels diagnostic
for HCC are above 400 ng/mL[10] in patients with LC and
a solid liver mass >2 cm with typical features in one imag-
ing study. The Italian and the American Association for
the Study of Liver Diseases guidelines consider a level
≥200 ng/mL as the cut-off point for diagnosis [8,9,11-13].
Higher levels of αFP are associated with poor prognostic
and survival rates in untreated patients with HCC or those
treated with liver transplantation or locoregional thera-
pies[4,8,14]. Some experts use αFP determinations and
liver ultrasound every 3 to 6 months to detect HCC in
patients with liver disease[15-17].
There is no concluding evidence available of the changes
of αFP levels throughout the disease yet[18]. The aim of
our study was to evaluate the progressive elevation of αFP
as a diagnostic test in patients with LC with an hepatic
lesion suspicious of HCC, and compare it to the transver-
sal determination of αFP ≥200 and 400 ng/mL.
Methods
This study was carried out in a single reference center
(Instituto Nacional de Ciencias Médicas y Nutrición "Sal-
vador Zubirán", National Institute of Medical Sciences
and Nutrition) the patients were studied in the time
period comprehended between January 1992 and Decem-
ber 2002, in the out-patient clinics of the Internal Medi-
cine and Gastroenterology services. Patients with the
diagnosis of LC and serial monthly determinations of αFP
levels, were included; the presence of cirrhosis was estab-
lished by biopsy or clinical data of chronic liver disease,
complications such as portal hypertension, esophageal
varices with or without a previous episode of bleeding,
splenomegaly, ascites with a previous episode of sponta-
neous bacterial peritonitis in the absence of other non
hepatic causes, hepatic encephalopathy in the absence of
other metabolic causes, hypoalbuminemia or hyperbiliru-
binemia in the absence of a known cause of the obstruc-
tion of the bile duct of at least one year of appearance with
progressive liver failure. All patients in the control group
had a minimal follow-up of one year with monthly deter-
mination of serum αFP levels and imaging studies every 3
to 6 months in order to assess they did not have HCC.
Ultrasound, Computed Tomography and Magnetic Reso-
nance Imaging were the diagnostic studies employed in
this work, the use of one or another depended on the
treating physicians' personal preferences.
Patients who were diagnosed with HCC by biopsy and
had monthly determinations of αFP levels were included
as cases. Patients in which the diagnosis of HCC was per-
formed by other means (e.g. alternative methods of imag-
ing diagnosis) were excluded. Files from the clinical
archive were reviewed. The exclusion criteria were:
patients with incomplete files, patients who did not meet
diagnosis criteria for LC or HCC, patients who were mis-
diagnosed, or who did not have at least three serial
monthly determinations of the levels of αFP reported. A
database was done registering clinical and pathological
information. All patients were classified based on the
Child-Pugh-Turcotte criteria (based on serum bilirubin
and albumin, ascites, neurological disorder and nutri-
tion), which are established prognostic factors in patients
with liver cirrhosis undergoing surgery [19,20].
The comparison of the clinical and pathological character-
istics between patients with and without an elevation of
αFP ≥ 200 and 400 ng/mL, as well as between those with
and without progressive elevation was done with stu-
dent's T test and Mann-Whitney's U for continuous varia-
bles with and without normal distribution, respectively.
For comparisons between more than three variables,
ANOVA and Tukey correction tests were used. Qualitative
variables were compared with Chi squared and exact
Fisher's test. A p value <0.05 was considered as significant.BMC Cancer 2007, 7:28 http://www.biomedcentral.com/1471-2407/7/28
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Sensitivity (i.e. True Positive Rate) and specificity (i.e.
True Negative Rate) were obtained by determining the lev-
els of αFP and its progressive elevation (the average
monthly increase of at least three measurements was
required), using SPSS statistical software version 10.0.
The Receiving Operating Characteristic (ROC) Analysis
curves and the corresponding area under the curve were
calculated to provide the accuracy of serum αFP in differ-
entiating HCC and LC patients. Non-parametric estimates
of the area under the ROC curve and the respective stand-
ard error were applied. Positive (PPV) and Negative (NPV)
predictive values were evaluated in our study considering
a prevalence of HCC of 5 and 10%. This was done with
EPIDAT software version 3.
The experimental research reported in this manuscript has
been performed with the approval of the Institutional
Review Board and Ethics Committee of the National Insti-
tute of Medical Sciences and Nutrition and is in compli-
ance with the Helsinki Declaration.
Results
We obtained 212 files of patients with the diagnosis of
HCC and 202 of patients with LC; from which 193 and 74
patients were included, respectively. The main causes of
exclusion were: incomplete files, lack of αFP determina-
tions, and an ambiguous diagnosis. No differences were
found among the patients considered as controls and
those excluded with LC regarding female gender (60 vs
63%, p = 0.9), age (51. 7 ± 1.7 vs 50.7 ± 2 years; p = 0.8),
Child (A/B/C 40/42/18 vs 55/34/11%, p = 0.4) and etiol-
ogy (alcoholic 11.2 vs 14, HCV 45 vs 50, cryptogenic 32
vs 15.9 p = 0.5), serum αFP levels (8.2 ± 2.2 vs 13 ± 4.4
ng/mL, p = 0.3). This analysis included only 85 of the
excluded patients due to an insufficient accuracy of the
medical files.
The minimal follow-up time of the patients with LC with-
out HCC (control cases) was of one year. The median fol-
low-up time of the patients with HCC was of 4.5 ± 1.2
months. Seventy-five percent of the patients with HCC
had a tumor size >5 cm. Tumors were multicentric in 22%
and poorly differentiated in 35%. General characteristics
of patients with HCC and LC are described in Table 1. We
found a greater proportion of men and a greater mean age
for patients with HCC. No differences regarding the
Child-Pugh score were found between groups. The αFP
level was significantly higher for patients with HCC com-
pared to patients with LC (8.2 ± 2.2 vs 271 ± 46 ng/mL,
respectively, p < 0.001). The progressive elevation of αFP
was greater in patients with HCC when compared to
patients with LC (0.34 ± 0.2 vs 62.3 ± 13.5 ng/mL/month,
respectively, p < 0.001) (Table 1). No differences were
found between the αFP elevation and the Child-Pugh
score, age, gender, etiology, differentiation grade and
tumour size amongst patients with HCC (Table 2). All
patients of both groups have at least 3 determinations of
αFP. The median number of αFP determinations was of 3,
range from 3 to 5 in both groups. The average increase of
the levels of αFP in patients with αFP basal levels <20 ng/
mL was of 15.8 ng/mL ± STD error 10.7, 67.9 ng/mL ± 38
in the patients with a basal αFP level between 20 and 100
ng/mL, and 76.3 ng/mL ± 18 for the patients with αFP lev-
els >200 ng/mL (p = 0.211). An elevation of αFP ≥7 ng/
mL/month in one determination was observed in 16.4%
and 70.8% of patients with LC and HCC, respectively;
while 1.8% and 43.2% of patients with LC and HCC
showed an elevation ≥7 ng/mL/month in two determina-
tions.
The sensitivity and specificity for the transversal determi-
nation of αFP varied according to its level as shown in
Table 3. For an αFP elevation ≥ 200 and 400 the specificity
is of 100% in both cases, with a sensitivity of 36.3 and
20.2%, respectively. The sensitivity and specificity for the
progressive determination of αFP are shown in Table 4. In
Figure 1, the areas under the ROC curves for the αFP levels
and the progression of αFP are shown. The area is signifi-
cantly greater for the αFP progressive elevation group (p <
0.05). In patients with an αFP progression rate ≥7 ng/mL/
month a sensitivity of 71.4% and a specificity of 100%
were found. We obtained an area under the curve of 0.587
with αFP levels ≥200 ng/ml, and 0.82 with the progressive
elevation of αFP ≥ 7 ng/mL/month, p < 0.001.
For patients with baseline αFP levels >7–20, sensitivity,
specificity, positive predictive value (PPV) and negative
predictive values (NPV) were: 50, 100, 100 and 78.7%,
respectively. For those with αFP baseline levels from 21 to
100, sensitivity, specificity, PPV and NPV were of 85, 100,
100 y 87.5%, respectively; between 101 and 200, these
values were of 50, 100, 100 y 25%, respectively.
Table 5 reports a PPV and NPV of ≥200 and 400 ng/mL, as
well as for the progressive elevation of αFP ≥7 ng/mL/
month taking into account a prevalence of 5 and 10%.
The positive and negative predictive values for the pro-
gressive elevation of αFP ≥7 ng/mL/month modified to a
10% prevalence are of: 98.8% and 96.92%, respectively;
while for a prevalence of 5% they were of 97.4% and
98.52%, respectively. This PPV could be used to reveal the
neoplastic nature of a liver mass occurring during surveil-
lance in patients without a transversal elevation of αFP.
Discussion
Many studies have evaluated the αFP serum levels as a
diagnostic test for HCC in patients with LC[9]. Due to the
poor prognosis of patients with HCC, in order to improve
survival, the therapeutic approach mainly depends on anBMC Cancer 2007, 7:28 http://www.biomedcentral.com/1471-2407/7/28
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early diagnosis. Besides being a diagnostic tool, determi-
nation of αFP has also been used to evaluate the response
to treatment and, moreover, to detect recurrences[10,21];
other studies have demonstrated that elevated levels of
αFP are an independent risk factor for the development of
HCC in patients with LC[5,6].
The causes of liver disease in our study were: alcoholic
liver disease, infection with either hepatitis B or hepatitis
C viruses, and cryptogenic (Table 1), as previously
reported; but with a different frequency[22,23]. Studies
have found differences in the αFP levels related to: the
tumoral size and tumor doubling time the Child-Pugh
score and the age of patients with HCC[21,24,25]; how-
ever this was not corroborated either in our study, or by
other authors[26-28]. Even though the patients in our
study had a close follow-up, 75% were found to have large
tumors (>5 cm). Although there are studies suggesting
that an intensive surveillance program may identify
smaller tumors, this is still controversial [29,30]. Further-
more, other studies have not found a statistically signifi-
cant relationship between the positivity of αFP and
tumoral size, degree of vascular invasion and the histolog-
ical differentiation grade of the tumor. Nevertheless,
patients with positive staining for αFP had a worse prog-
nosis than those with negative staining [31].
The sensitivity and specificity of αFP for the detection of
HCC has been reported from 17 to 76% and 80 to 100%,
respectively (Table 6)[8,18,32-36]. We found that an αFP
value ≥200 and 400 ng/mL has a sensitivity of 36.3% and
20.2%, respectively, and specificity of 100% in both
groups; a study with 340 patients found similar
results[18]. There can be a transitory elevation of αFP in
patients with cirrhosis and exacerbations of infectious
hepatitis[37]. Alpha-fetoprotein levels are not elevated in
many patients with HCC, which makes the transversal
measuring of the αFP elevation not an optimal diagnostic
test. Moreover the clinical usefulness of alpha-fetoprotein
in hepatocellular carcinoma management is still being
debated [38].
We observed that an αFP monthly average progression
rate ≥7 ng/mL/month of at least 3 determinations, has a
sensitivity and specificity of 71.4 and 100%, respectively.
The elevation of αFP after one month of follow-up some-
times did not show any changes; we realized that 3 deter-
minations were required in order to have a more accurate
test.
The αFP progression rate and a tumor-suggestive image –
together – could be employed to diagnose HCC. This
approach could be of special interest in patients with LC
and clinical suspicious of HCC, who are not candidates
neither for biopsy nor for surgical treatment and who do
not reach an αFP level ≥200 ng/mL; they could benefit of
being diagnosed with HCC and initiate treatment without
waiting for αFP levels to reach a value ≥ 200 or ≥400 ng/
Table 1: General characteristics of the patients with liver cirrhosis (LC) and hepatocellular carcinoma (HCC)
Characteristics LC HCC P
Female 60% 46% 0.049
Male 40% 64%
Age 51.7 ± 1.7 59.9 ± 0.96 0.001
Child-Pugh Score
A 40% 47%
B 42% 37.3% 0.48
C 18% 15%
Etiology
Alcoholic 11.2% 26%
HBV 0% 7.2%
HCV 45% 30% 0.001
Cryptogenic/autoimmune 32% 5.7%
Undetermined or absent 11% 30.4%
αFP 8.2 ± 2.2 271 ± 46 0.001
αFP > 400 0% 19.6% 0.001
Progressive monthly elevation 0.34 ± .161 62.3 ± 13.5 0.001
Increase of 5 ng/mL/month or greater 1.7% 76.2% 0.001BMC Cancer 2007, 7:28 http://www.biomedcentral.com/1471-2407/7/28
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mL. Many patients with a suggestive image of HCC can
not be biopsied due either to coagulation abnormalities
or location of the tumor or due to the presence of massive
ascites among other causes; also, many patients do not
reach the value of 200 or 400 ng/mL (in our study 63.7%
and 79.8%, respectively), reason why the progressive ele-
vation of αFP could help to establish the diagnosis with-
out the need of biopsy and could allow the inclusion of
these patients to treatment study protocols. On the other
hand, the continuous increase of aFP should induce the
Table 2: Clinical and pathological factors associated with the levels of αFP in patients with hepatocellular carcinoma (HCC).
Associated Factors Levels of FP α(ng/mL) P
Child-Pugh Score
A 171 ± 34 0.74
B2 2 9  ±  7 3
C2 1 1  ±  8 0
Mean age
<60 years 267 ± 64 0.78
>60 years 132 ± 19
Gender
Female 164 ± 43 0.49
Male 238 ± 53
Etiology
HBV 368 ± 36 0.16
HCV 137 ± 23
Cryptogenic/autoimmune 52 ± 23
Alcoholic 275 ± 99
Undetermined or absent 258 ± 90
Degree of differentiation
Well 167 ± 29 0.16
Moderate 271 ± 87
Poor 140 ± 10
Tumor Size
< 5 cm 267 ± 64 0.66
> 5 cm 132 ± 19
Table 3: Sensitivity and Specificity for the transversal determinations of αFP for the diagnosis of hepatocellular carcinoma (HCC)
αFP (ng/mL) Sensitivity (%) Specificity (%)
0.3 99.5 0
2.5 92.2 29.7
5.1 83.9 57
7.5 77.7 72
10.2 71 88
15.5 64.2 96
20.3 60.6 96
25.6 58.5 96
51.35 51.8 99
72.5 48.7 99
98.65 47.2 99
111 45.6 99
130 43 99
160 38.9 100
190 36.3 100
215 34.7 100
280 24.4 100
330 21.8 100
395 20.2 100
415 18.7 100BMC Cancer 2007, 7:28 http://www.biomedcentral.com/1471-2407/7/28
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start of research protocols for HCC and eventually enroll-
ment of these patients in a transplantation program even
before the tumor becomes detectable.
There are few existing studies that evaluate the utilization
of serial determinations of αFP for the diagnosis of HCC
and none compares it to the transversal determination of
αFP at its best specificity level (≥ 200 ng/mL)[18,39,40]. A
study demonstrated that a fast and sudden elevation of
αFP in patients with liver lesions detected more HCC
when compared to other elevation patterns in patients
with cirrhosis and hepatic lesions[41]. Many studies have
been done to increase the specificity of the measurement
of αFP for the diagnosis of HCC depending on its binding
capacity to different molecules; however its use is expen-
sive and it is not widely available[2,42].
Even though high αFP levels may be more indicative of
HCC in patients with LC without viral infection [9], the
type of viral infection (HBV or HCV) does not seem to
have a direct influence on the serum αFP levels in patients
with HCC [21,43]. A limitation of this study are the differ-
ences in etiology between both study groups, mainly
regarding HBV patients, which could cause the differences
in the αFP levels. Also, since it is a retrospective study, it
was not possible to match both groups from the begin-
ning. Prospective studies need to be done in order to cor-
roborate our findings and to perform a cost-benefit
analysis of this test. Nevertheless, these studies might be
difficult to perform; as a matter of fact, if we consider that
approximately 5% of the patients with viral hepatitis and
LC develop HCC within a year, the number of patients
with LC needed to carry out such studies is rather large.
Conclusion
In conclusion, the average progressive elevation of αFP ≥7
ng/mL/month and a tumor-suggestive image – together –
in patients with LC could be a very useful tool for the
detection of HCC, especially in those patients without a
transversal αFP elevation ≥200 ng/mL.
Table 4: Sensitivity and Specificity for the progression rate of αFP
Progression rate (ng/mL/month) Sensitivity (%) Specificity (%)
-3.43 100 0
0.1065 95.2 56
0.2335 92.1 70
0.66 87.3 82
0.94 84.1 85
1.6 81 89
2.15 81 94
2.64 81 95
3.01 79.4 95
3.29 79.4 97
4.04 77.8 97
4.75 77.8 99
5.07 76.2 99
5.47 74.6 99
5.84 71.4 100
8.87 66.7 100
10.8 65.1 100
16.83 52.4 100
20.4 46 100
28.94 38.1 100
Table 5: Positive Predictive Value (PPV) and Negative Predictive Value (NPV) for the diagnosis of HCC with αFP values ≥200, αFP 
values ≥ 400 ng/mL and with the progressive elevation of αFP of 5 ng/mL with a prevalence of 5 and 10%.
αFP HCC Prevalence (%) PPV (%) NPV (%)
≥200 ng/ml 10 97.58 93.4
5 95.03 96.7
≥400 ng/ml 10 95.7 91.86
5 91.4 95.97
Elevation ≥7 ng/ml/month 10 98.7 96.92
5 97.4 98.52BMC Cancer 2007, 7:28 http://www.biomedcentral.com/1471-2407/7/28
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ROC curve for the progressive elevation of αFP and αFP levels Figure 1
ROC curve for the progressive elevation of αFP and αFP levels. The area under the curve for the progressive elevation of αFP 
is significantly greater than the area under the curve for αFP levels (p < 0.05). (AUC = Area Under the Curve).
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Table 6: Comparison of sensitivity and specificity of the αFP levels for the diagnosis of hepatocellular carcinoma (HCC) of several 
studies
Authors αFP 10–16 (ng/mL) αFP 20 (ng/mL) αFP 100 (ng/mL) αFP 200 (ng/mL) αFP 300 (ng/mL) αFP 400 (ng/mL)
S (%) E (%) S (%) E (%) S (%) E (%) S (%) E (%) S (%) E (%) S (%) E (%)
Oka et al 1994 39 76 13 97
Pateron et al 1994 50 86 21 93
Peng et al 1999 65 87 45 100
Tong et al 2001 41 94
Trevisani et al 2001 62.4 89.4 60 90.6 31.2 98.8 22 99 22.4 99.4 17.1 99.4
Gebo et al 2002* 60 0–64 100
Nguyen et al 2002 78.4 61.1 63 80 41.4 97.3 32 100
Gupta et al 2003* 41–65 80–94
Farinati et al 2006 54 18
Arrieta 2007+ 63.2 95.9 60.6 95.9 47.2 99 36.3 100 22.8 100 20.2 100
S = sensitivity, E = specificity.
* Literature review
+ Present studyBMC Cancer 2007, 7:28 http://www.biomedcentral.com/1471-2407/7/28
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